 Exagen Inc NASDAQ: XGN shares are moving after the Companys Q2 2021 revenue increased 43 YY to 12.8 million due to increased testing volumes, beating the consensus of 11.48 million. Its flagship AVISE CTD test, including AVISE Lupus, raked in 10.4 million in sales with the 94 YY growth, indicating an acceleration from 22 YoY recorded in Q1 2021. 